Tofacitinib Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

189

Total Trials

Recruiting

Completed

313,973

Total Enrollment

States

Tofacitinib Evidence & Publications

448 peer-reviewed publications + per-arm primary-outcome data from 46 pivotal trials.

See published evidence →

Tofacitinib Clinical Trials

Sortable list of all 189 Tofacitinib trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Tofacitinib History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Tofacitinib — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Tofacitinib updates

See full history →

Tofacitinib Label Adds Boxed Warning for Serious Infections, Mortality· Jun 9, 2026
Tofacitinib (Xeljanz) Label Adds Boxed Warning for Serious Risks· Jun 8, 2026
Tofacitinib Label Receives Boxed Warning for Serious Risks· Jun 5, 2026
Tofacitinib Label Adds Boxed Warning for Serious Infections, Mortality, MACE,…· Jun 4, 2026
Tofacitinib (Xeljanz) Label Adds Boxed Warning for Serious Risks· Jun 2, 2026
Tofacitinib (Xeljanz) Label Adds Boxed Warning for Serious Risks· May 31, 2026
Tofacitinib Long-Term Safety in JIA: Lab Abnormalities, TEAEs Reported· Mar 23, 2026
Xeljanz XR (Tofacitinib) Receives Supplemental FDA Approval for Efficacy· Mar 6, 2026

What Is Tofacitinib?

Tofacitinib is an FDA-approved medication for rheumatoid arthritis and psoriatic arthritis. It is also known by the brand name Xeljanz. Tofacitinib is a type of medicine called a Janus kinase (JAK) inhibitor. It works by blocking certain enzymes in the body that play a role in inflammation and immune responses. By inhibiting these enzymes, tofacitinib can help reduce inflammation and slow down the progression of certain autoimmune diseases.

Beyond its approved uses, tofacitinib is being investigated in clinical trials for a wide range of other conditions. These include ulcerative colitis, alopecia areata, psoriasis, axial spondylarthritis, dermatomyositis, and various other inflammatory and autoimmune disorders. The earliest clinical trial for tofacitinib began on July 16, 2010, with the latest trial projected to conclude on April 28, 2026. Overall, 189 trials involving tofacitinib have enrolled over 313,973 participants.

Uses and Conditions Under Study

Tofacitinib is being studied for its potential to treat a variety of conditions, primarily focusing on inflammatory and autoimmune diseases due to its mechanism as a JAK inhibitor.

Rheumatoid Arthritis and Psoriatic Arthritis: These are chronic autoimmune diseases that cause inflammation in the joints. Tofacitinib is already approved for these conditions and continues to be studied in 41 trials for rheumatoid arthritis and 9 trials for psoriatic arthritis to further understand its efficacy, safety, and optimal use, including for related conditions like rheumatoid arthritis-related interstitial lung disease (RA-ILD).
Inflammatory Bowel Diseases: This category includes conditions like ulcerative colitis, which causes chronic inflammation of the colon. Tofacitinib is being investigated for its ability to reduce inflammation in the gastrointestinal tract, with 13 trials specifically for ulcerative colitis and other trials for inflammatory bowel disease generally.
Skin and Hair Conditions: As an autoimmune disease, alopecia areata causes hair loss when the immune system attacks hair follicles. Psoriasis and palmoplantar pustulosis are chronic inflammatory skin diseases. Tofacitinib is being studied in 8 trials for alopecia areata, 4 trials for alopecia universalis, and 5 trials for psoriasis, as well as for conditions like dermatomyositis, atopic dermatitis (eczema), and skin conditions associated with Down syndrome, to help suppress the immune response that leads to these symptoms.
Other Autoimmune and Inflammatory Disorders: Tofacitinib is also under investigation for conditions such as Takayasu arteritis (5 trials), axial spondylarthritis (a type of inflammatory back pain), and systemic lupus erythematosus (SLE), where immune system dysregulation plays a key role.
Infections and Cancer: Some trials are exploring tofacitinib's role in managing severe inflammation in conditions like COVID-19 (4 trials) and its potential in pancreatic cancer.
Healthy Volunteers: 11 trials have involved healthy participants, typically to study how the drug is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) and to assess its safety profile.

Dosing

Tofacitinib has been studied in various dosage forms and strengths, primarily as an oral medication, but also in topical formulations.

The most common oral dosage forms are tablets, including both immediate-release and modified-release formulations. Capsules have also been investigated. Common oral strengths studied include 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 60 mg. Higher investigational doses such as 200 mg and 400 mg have also been explored. Modified-release tablets have been studied in strengths like 11 mg and 22 mg.

Oral tofacitinib is typically taken twice daily (BID), such as 5 mg BID or 10 mg BID, though some studies have explored once-daily (QD) dosing, for example, 60 mg QD. For specific conditions, tofacitinib has also been studied in combination with other medications, such as venetoclax or methotrexate.

Topical formulations have also been developed and studied. These include medicated nail lacquer containing 2% tofacitinib, as well as ointments and creams with concentrations like 0.5% and 1% tofacitinib. Topical products are generally applied once daily, as seen with the nail lacquer for home use.

Side Effects

In clinical trials, the most common side effect reported for Tofacitinib was upper respiratory tract infection. Approximately 7.1% of patients taking Tofacitinib experienced this, compared to 5.4% on placebo. Other common side effects included:

Lymphopenia (a low white blood cell count): 6.5% of patients on Tofacitinib experienced this, compared to 2.3% on placebo.
Nasopharyngitis (common cold): 6.0% of patients on Tofacitinib experienced this, compared to 4.3% on placebo.
Hypertension (high blood pressure): 5.4% of patients on Tofacitinib experienced this, compared to 1.1% on placebo.
Urinary tract infection: 5.2% of patients on Tofacitinib experienced this, compared to 2.7% on placebo.
Headache: 5.0% of patients on Tofacitinib experienced this, compared to 3.8% on placebo.
Increased alanine aminotransferase (a liver enzyme): 3.1% of patients on Tofacitinib experienced this, compared to 1.4% on placebo.

Clinical Trial Results

Tofacitinib has been evaluated in clinical trials for various conditions, including rheumatoid arthritis, ulcerative colitis, and juvenile idiopathic arthritis.

Rheumatoid Arthritis (NCT01164579)

In a study of patients with early rheumatoid arthritis, Tofacitinib was evaluated alone and in combination with methotrexate (MTX). Patients treated with Tofacitinib alone or in combination with MTX showed greater improvements in disease activity compared to MTX alone.

For the ACR20 response (a 20% improvement in symptoms), up to 66.7% of patients on Tofacitinib alone achieved this, and up to 77.1% on Tofacitinib plus MTX, compared to up to 48.7% on MTX alone.
For the ACR50 response (a 50% improvement), up to 50.0% of patients on Tofacitinib alone achieved this, and up to 57.1% on Tofacitinib plus MTX, compared to up to 29.7% on MTX alone.
For the ACR70 response (a 70% improvement), up to 33.3% of patients on Tofacitinib alone achieved this, and up to 34.3% on Tofacitinib plus MTX, compared to up to 21.6% on MTX alone.

Tofacitinib also demonstrated a greater reduction in MRI-assessed synovitis and bone marrow edema scores compared to methotrexate alone. For example, at Month 3, synovitis scores decreased by 0.69 with Tofacitinib and 0.80 with Tofacitinib plus MTX, compared to 0.17 with MTX alone. Erosion scores showed a reduction or less progression with Tofacitinib compared to methotrexate.

Ulcerative Colitis (NCT01458951 and NCT01465763)

Two studies investigated Tofacitinib 10 mg twice daily for moderately to severely active ulcerative colitis. At Week 8, Tofacitinib showed superior results compared to placebo across several key measures:

Clinical response was achieved by an average of 57.5% of patients on Tofacitinib, compared to 30.7% on placebo.
Mucosal healing was observed in an average of 29.9% of patients on Tofacitinib, compared to 13.6% on placebo.
Clinical remission was achieved by an average of 17.7% of patients on Tofacitinib, compared to 5.9% on placebo.

Juvenile Idiopathic Arthritis (NCT01500551)

In a long-term study for juvenile idiopathic arthritis (JIA), including the pJIA (polyarticular JIA) analysis set, Tofacitinib 5 mg twice daily demonstrated sustained improvements in disease

Currently Recruiting Trials

Tofacitinib, known commercially as Xeljanz, is currently being investigated in numerous clinical trials for a wide range of conditions. These studies aim to understand its efficacy and safety in new patient populations and in combination with other therapies. One Phase 2 study, NCT07547930, sponsored by The First Affiliated Hospital of Xiamen University, is recruiting 8 participants to evaluate tofacitinib for glucocorticoid-resistant moderate-to-severe Thyroid Eye Disease. Another study, NCT07343635, from The Fourth Affiliated Hospital of Zhejiang University School of Medicine, is a single-blind cohort study with 186 patients, assessing tofacitinib combined with anti-inflammation treatment and doxycycline for mild to moderate Erythematotelangiectatic Rosacea. Duke University is sponsoring a Phase 3 trial, NCT06654882, enrolling 400 participants with Polyarticular Course Juvenile Idiopathic Arthritis (JIA) to compare sequential medications after TNFi failure, including tofacitinib. For patients with Sjogren's Syndrome, the National Institute of Dental and Craniofacial Research (NIDCR) is conducting a Phase 2 safety study, NCT07281456, targeting 60 participants. Shaikh Zayed Hospital, Lahore, is running a Phase 4 trial, NCT07554820, with an enrollment target of 120, to observe major adverse cardiovascular events in rheumatoid arthritis patients treated with tofacitinib and statins versus TNF inhibitors. The All India Institute of Medical Sciences, Bhubaneswar, is evaluating tofacitinib as an add-on therapy for Oral Lichen Planus in a Phase 4 study, NCT07131813, enrolling 60 patients. For Psoriasis, Lahore General Hospital is comparing oral methotrexate and tofacitinib in an Early Phase 1 study, NCT07261306, with 75 participants. Assistance Publique - Hôpitaux de Paris is conducting a Phase 3 study, NCT04871191, for patients with Granulomatosis With Polyangiitis, aiming for 42 participants to identify promising salvage therapies, including tofacitinib. Other notable recruiting trials include:

A study on Telitacicept combined with tofacitinib for Refractory Rheumatoid Arthritis, NCT06979271, enrolling 20 participants.
A Phase 2 trial of tofacitinib 2% cream for Cutaneous T-cell Lymphoma, NCT06698822, with 20 participants.
A comparison of secukinumab with tofacitinib for moderate to severe Hidradenitis Suppurativa, NCT06707246, targeting 60 Chinese patients.
A study combining methotrexate with tofacitinib in Rheumatoid Arthritis, NCT06301373, seeking 130 participants.
An evaluation of vedolizumab with tofacitinib in adults with Ulcerative Colitis, NCT06095128, enrolling 65 participants.
A Phase 4 trial of 3T therapy (tacrolimus, tofacitinib, thalidomide) for MDA5-positive Dermatomyositis, NCT06438679, with 133 participants.
A Phase 2 study comparing HS-10374 to placebo and tofacitinib in Psoriatic Arthritis, NCT06176508, enrolling 160.
A Phase 3 study on induction and tapering therapy with tofacitinib and glucocorticoid in Polymyalgia Rheumatica, NCT06172361, with 98 participants.
A Phase 4 study, NCT06112665, comparing tofacitinib to placebo in early active Axial Spondyloarthritis, enrolling 104.
A Phase 2 study of tocilizumab and tofacitinib in Vascular Behçet's Syndrome, NCT05845723, with 81 participants.
A Phase 4 study comparing tofacitinib and methotrexate in Takayasu's Arteritis, NCT05102448, enrolling 76.
A Phase 2 study on Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction, NCT03681275, targeting 70 participants.

Where to Participate

Clinical trials for tofacitinib are currently recruiting participants across a wide geographical area, with study sites located in 47 different locations across 24 states. This broad reach allows more individuals to potentially access these investigational treatments. The top recruiting locations include:

Houston, Texas (2 sites)
Columbus, Ohio (2 sites)
New York, New York (2 sites)
Newport Beach, California (1 site)
San Francisco, California (1 site)
Stanford, California (1 site)
Gainesville, Florida (1 site)
Orlando, Florida (1 site)
Tampa, Florida (1 site)
Roswell, Georgia (1 site)

Eligibility for these studies is broad, welcoming participants aged from 2 to 88 years. Both male and female individuals are eligible to join. Many trials also accept healthy volunteers, and children are specifically eligible for participation in certain studies.

Development Timeline

The development journey for tofacitinib began with its first clinical trial on July 16, 2010, and continues with studies projected as far out as April 28, 2026. Over this period, a substantial research effort has led to a total of 189 trials, enrolling an impressive 313,973 participants. Initial investigations into tofacitinib focused on conditions such as IBS-C and hyperphosphatemia. However, the research pipeline quickly expanded, exploring its potential across a diverse range of autoimmune and inflammatory diseases. Early and mid-stage development saw a significant number of Phase 2 trials, totaling 49, which are crucial for evaluating efficacy and safety in larger patient groups. As development progressed, 35 Phase 4 trials were initiated, often after initial approval, to further monitor the drug's long-term effects and explore new applications. There were also 27 Phase 3 trials, which are typically pivotal studies for regulatory approval. Pfizer has been a primary driver in tofacitinib's development, sponsoring 44 trials. Other notable sponsors include the Second Affiliated Hospital, School of Medicine, Zhejiang University, and Shanghai Zhongshan Hospital, among many others globally. The range of conditions studied has grown remarkably, moving from initial indications to include a wide array of diseases such as Psoriatic Arthritis, Alopecia Areata, Rheumatoid Arthritis, Psoriasis, Takayasu Arteritis, and Ulcerative Colitis. More recently, studies have explored its use in conditions like Thyroid Eye Disease, Cutaneous T-cell Lymphoma, and even rare conditions like Blau Syndrome, highlighting the continuous expansion of research into tofacitinib's therapeutic potential.

Tofacitinib Development Timeline

Clinical trial activity from 2002 to 2026.

2026

NCT07522801PHASE2not yet recruiting

A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

93 enrolled

NCT07352566PHASE4not yet recruiting

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

10 enrolled

NCT07055529EARLY_PHASE1not yet recruiting

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

64 enrolled

NCT07406035PHASE2not yet recruiting

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

156 enrolled

NCT07547930PHASE2recruiting

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

8 enrolled

NCT07530367PHASE3not yet recruiting

A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

135 enrolled

NCT07313072PHASE2not yet recruiting

Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

10 enrolled

NCT07406204PHASE4not yet recruiting

Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)

78 enrolled

NCT07343635NArecruiting

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

186 enrolled

NCT06654882PHASE3recruiting

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

400 enrolled

NCT07487311recruiting

A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

80 enrolled

NCT07297069PHASE2not yet recruiting

Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

60 enrolled

2025

NCT07211932not yet recruiting

Tofacitinib in Juvenile Idiopathic Arthritis

58 enrolled

NCT07281456PHASE2recruiting

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

60 enrolled

NCT07554820PHASE4recruiting

Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

120 enrolled

NCT07131813PHASE4recruiting

Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus

60 enrolled

NCT07138898PHASE2not yet recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

80 enrolled

NCT07261306EARLY_PHASE1recruiting

Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

75 enrolled

NCT06945666PHASE4not yet recruiting

A Study of Iguratimod in Combination With Tofacitinib in RA Patients

200 enrolled

NCT04871191PHASE3recruiting

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

42 enrolled

NCT06979271recruiting

Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

20 enrolled

NCT07008846PHASE3active not recruiting

Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

96 enrolled

NCT06923228PHASE2completed

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

3 enrolled

NCT06698822PHASE2recruiting

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

20 enrolled

NCT06998875PHASE4recruiting

A Prospective Cohort Study on Primary Cutaneous Amyloidosis

56 enrolled

NCT07044141PHASE1active not recruiting

Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

20 enrolled

NCT06465732PHASE4not yet recruiting

Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

220 enrolled

NCT06687551PHASE4not yet recruiting

JAK Inhibitor Dose TAPering Strategy Study

308 enrolled

2024

NCT07472166PHASE4completed

Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

34 enrolled

NCT06810050PHASE2completed

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

180 enrolled

NCT06707246NArecruiting

A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

60 enrolled

NCT06689982EARLY_PHASE1not yet recruiting

Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

12 enrolled

NCT06625450PHASE4not yet recruiting

TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS

75 enrolled

NCT06301373NArecruiting

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

130 enrolled

NCT06573593recruiting

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

150 enrolled

NCT06393972PHASE2not yet recruiting

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

25 enrolled

NCT06498089PHASE4recruiting

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

124 enrolled

NCT06095128PHASE4recruiting

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

65 enrolled

NCT06418529completed

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

21,340 enrolled

NCT06201715NAunknown

Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

24 enrolled

NCT06438679PHASE4enrolling by invitation

3T Therapy in the Treatment of MDA5-positive Dermatomyositis

133 enrolled

NCT06176508PHASE2recruiting

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

160 enrolled

NCT06172361PHASE3recruiting

Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica

98 enrolled

2023

NCT06044844PHASE2unknown

Effectiveness of Tofacitinib in Systemic Sclerosis

44 enrolled

NCT06202560NAcompleted

Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study

11 enrolled

NCT06020144PHASE3active not recruiting

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

459 enrolled

NCT06112665PHASE4recruiting

ToFAcitinib in Early Active Axial SpondyloarThritis:

104 enrolled

NCT06114407PHASE2unknown

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

184 enrolled

NCT06011343PHASE2/PHASE3unknown

Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

22 enrolled

NCT06119490EARLY_PHASE1recruiting

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

30 enrolled

NCT06278402PHASE3completed

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

30 enrolled

NCT05112263NAunknown

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

96 enrolled

NCT05662228PHASE2active not recruiting

Therapies for Down Syndrome Regression Disorder

66 enrolled

NCT05845723PHASE2recruiting

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

81 enrolled

NCT05814939PHASE2completed

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

180 enrolled

NCT05803135PHASE4unknown

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

138 enrolled

NCT05749666PHASE3unknown

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

50 enrolled

2022

NCT05625581unknown

Tofatib Treatment for IgG4-related Disease

40 enrolled

NCT05487963PHASE1/PHASE2completed

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

40 enrolled

NCT05326464PHASE3active not recruiting

Tofacitinib in Recurrent GBM Patients

17 enrolled

NCT05048238PHASE1completed

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

7 enrolled

NCT05104723PHASE1/PHASE2completed

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

10 enrolled

NCT05246293PHASE2unknown

Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.

60 enrolled

NCT06157905EARLY_PHASE1completed

Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata

9 enrolled

NCT06474078NAcompleted

Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

20 enrolled

NCT05165771PHASE2withdrawn

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment

0 enrolled

NCT05400889PHASE2unknown

Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

10 enrolled

NCT05606107PHASE4unknown

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

230 enrolled

NCT05348213PHASE2recruiting

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

76 enrolled

NCT05431283unknown

Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy

100 enrolled

NCT05728008completed

Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.

100 enrolled

NCT05313620PHASE4recruiting

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

30 enrolled

NCT04768504PHASE2terminated

Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

2 enrolled

NCT05133297PHASE2completed

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

101 enrolled

NCT05186623recruiting

Prediction Model for Response to Biologics and Small Molecular Agent for UC

300 enrolled

NCT04876781recruiting

Korean Post-marketing Surveillance for Xeljanz XR

200 enrolled

NCT05151848PHASE4unknown

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

100 enrolled

NCT06310057PHASE4completed

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

92 enrolled

2021

NCT05087589PHASE2unknown

Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

10 enrolled

NCT05080218PHASE4completed

COVID-19 VaccinE Response in Rheumatology Patients

841 enrolled

NCT05102448PHASE4recruiting

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

76 enrolled

NCT04624230PHASE3active not recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

118 enrolled

NCT04985955PHASE1completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

12 enrolled

NCT04944524PHASE4unknown

Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA

66 enrolled

NCT04925973PHASE2active not recruiting

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

24 enrolled

NCT04927000PHASE4unknown

The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

170 enrolled

NCT04496960PHASE1/PHASE2active not recruiting

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

23 enrolled

NCT04798287completed

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

105,711 enrolled

NCT04772248completed

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

105,711 enrolled

NCT04580277PHASE2terminated

Tofacitinib For Treatment Of Chronic Pouchitis

6 enrolled

NCT04721821completed

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

7,807 enrolled

NCT04799262PHASE2completed

Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica

14 enrolled

2020

NCT04424303completed

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

152 enrolled

NCT04311567PHASE4terminated

Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease

3 enrolled

NCT04246372PHASE2completed

Tofacitinib for Immune Skin Conditions in Down Syndrome

47 enrolled

NCT04610476PHASE3unknown

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

270 enrolled

NCT04468425PHASE1completed

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

14 enrolled

NCT04415151PHASE2terminated

Tofacitinib for Treatment of Moderate COVID-19

24 enrolled

NCT04613219unknown

Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease

80 enrolled

NCT04469114PHASE3completed

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

289 enrolled

NCT04338204completed

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

102 enrolled

NCT04552197PHASE1completed

A Study of JNJ-64251330 in Healthy Participants

36 enrolled

NCT04529876completed

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

29,464 enrolled

NCT07101471completed

Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

296 enrolled

NCT04062695PHASE2unknown

Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement

80 enrolled

NCT04413617PHASE2completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

460 enrolled

NCT04412252PHASE2withdrawn

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

0 enrolled

NCT04390061PHASE2unknown

TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia

116 enrolled

NCT04338711PHASE1completed

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

23 enrolled

NCT05638932completed

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

1,442 enrolled

NCT04431895EARLY_PHASE1completed

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

19 enrolled

NCT04750317PHASE2completed

Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia

414 enrolled

NCT04449224unknown

Comparative Effectiveness of Targeted Therapy in RA Patients

506 enrolled

NCT04332042PHASE2unknown

TOFAcitinib in SARS-CoV2 Pneumonia

50 enrolled

NCT04928066PHASE4completed

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

100 enrolled

NCT03976245PHASE4recruiting

Advanced Therapeutics in Rheumatoid Arthritis (RA)

144 enrolled

NCT04299971PHASE4unknown

Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

130 enrolled

NCT04175886completed

Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project

10 enrolled

NCT04141904PHASE1/PHASE2terminated

Tofacitinib in Depression (TIDE)

2 enrolled

2019

NCT04973033NAcompleted

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

10 enrolled

NCT04485325PHASE4completed

Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

92 enrolled

NCT04111614PHASE1completed

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

12 enrolled

NCT03885713PHASE4completed

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

180 enrolled

NCT03681275PHASE2recruiting

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

70 enrolled

NCT04034238PHASE1completed

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

19 enrolled

NCT04464642PHASE4unknown

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

110 enrolled

NCT03970837PHASE3terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

1,764 enrolled

NCT03980483PHASE3completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

1,537 enrolled

NCT03793439PHASE1completed

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

5 enrolled

NCT03910543PHASE1completed

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

15 enrolled

NCT03580343PHASE2unknown

Tofacitinib for Inflammatory Eye Disease

5 enrolled

NCT03868072PHASE1completed

Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

40 enrolled

NCT03800979PHASE4completed

Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata

19 enrolled

NCT03981900completed

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

314 enrolled

NCT03598959PHASE2unknown

Tofacitinib Combined With Chidamide in R/R ENKTCL

20 enrolled

2018

NCT04403776PHASE1completed

PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation

26 enrolled

NCT03755466PHASE2unknown

Examination of Efficacy and Safety of Baricitinib in RA Patients

90 enrolled

NCT03486457PHASE3completed

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

204 enrolled

NCT03502616PHASE3completed

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

270 enrolled

NCT03000439PHASE3completed

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

100 enrolled

NCT03504072PHASE4unknown

Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh

174 enrolled

2017

NCT03387423completed

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis

1,459 enrolled

NCT03440892unknown

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

2,500 enrolled

NCT03274076PHASE1/PHASE2completed

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

15 enrolled

NCT03736161PHASE3completed

Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

61 enrolled

NCT03112148PHASE1completed

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

24 enrolled

NCT03738956PHASE2/PHASE3unknown

Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial

30 enrolled

NCT03288324PHASE1/PHASE2completed

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

13 enrolled

NCT03103412PHASE1completed

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

32 enrolled

NCT03159936EARLY_PHASE1terminated

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

5 enrolled

NCT03002649PHASE1completed

Study of Tofacitinib in Refractory Dermatomyositis

10 enrolled

NCT06688838enrolling by invitation

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

24 enrolled

2016

NCT02996500PHASE2completed

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

269 enrolled

NCT03011281unknown

Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis

378 enrolled

NCT02812342PHASE2completed

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

10 enrolled

NCT02592434PHASE3completed

Efficacy Study Of Tofacitinib In Pediatric JIA Population

225 enrolled

NCT02321930PHASE4completed

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

37 enrolled

2015

NCT02535689PHASE1completed

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

34 enrolled

NCT02487433PHASE1completed

A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers

18 enrolled

NCT02566967PHASE3completed

An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective

20 enrolled

NCT02299297PHASE2completed

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

12 enrolled

2014

NCT02312882NAcompleted

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

40 enrolled

NCT02281552PHASE3completed

A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis

209 enrolled

NCT02193815PHASE1completed

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

15 enrolled

NCT02187055PHASE4completed

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

1,152 enrolled

NCT02197455PHASE2completed

Tofacitnib for the Treatment of Alopecia Areata and Variants

30 enrolled

NCT02147587PHASE2completed

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

112 enrolled

NCT02084875PHASE1completed

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

24 enrolled

NCT02092467PHASE4completed

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

4,372 enrolled

NCT01976364PHASE3completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

686 enrolled

NCT01877668PHASE3completed

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

422 enrolled

2013

NCT02001181PHASE2completed

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

69 enrolled

NCT01882439PHASE3completed

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

395 enrolled

NCT01932372completed

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

9,968 enrolled

NCT01831466PHASE2completed

Tofacitinib Ointment For Chronic Plaque Psoriasis

476 enrolled

NCT01786668PHASE2completed

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

208 enrolled

NCT01710046PHASE2completed

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

12 enrolled

NCT01500551PHASE2/PHASE3completed

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

302 enrolled

2012

NCT01741493PHASE1completed

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

67 enrolled

NCT01731327PHASE1completed

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

20 enrolled

NCT01458951PHASE3completed

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

547 enrolled

NCT01599377PHASE1completed

Tofacitinib Bioequivalence Study Comparing Tablets And Capsules

50 enrolled

NCT01465763PHASE3completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

614 enrolled

2011

NCT01499004PHASE1completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

30 enrolled

NCT01375127completed

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

83 enrolled

2010

NCT01164579PHASE2completed

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

109 enrolled

2007

NCT03414502PHASE3recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

400 enrolled

2005

NCT01745055PHASE1completed

Co-Administration Of Methotrexate And CP-690,550

12 enrolled

2002

NCT01736696PHASE1completed

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

59 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Rheumatoid Arthritis	NCT07554820	Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	recruiting	PHASE4	120
	NCT06979271	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	recruiting	N/A	20
	NCT06301373	Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis	recruiting	NA	130
	NCT06418529	A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis	completed	N/A	21,340
	NCT06020144	A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs	active not recruiting	PHASE3	459
	NCT05803135	Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis	unknown	PHASE4	138
	NCT05246293	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	unknown	PHASE2	60
	NCT05165771	Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment	withdrawn	PHASE2	0
	NCT05606107	To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks	unknown	PHASE4	230
	NCT05133297	The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis	completed	PHASE2	101
	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
	NCT04927000	The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis	unknown	PHASE4	170
	NCT04798287	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	completed	N/A	105,711
	NCT04772248	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints	completed	N/A	105,711
	NCT04311567	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	terminated	PHASE4	3
	NCT04529876	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept	completed	N/A	29,464
	NCT04413617	TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	completed	PHASE2	460
	NCT04449224	Comparative Effectiveness of Targeted Therapy in RA Patients	unknown	N/A	506
	NCT03976245	Advanced Therapeutics in Rheumatoid Arthritis (RA)	recruiting	PHASE4	144
	NCT04175886	Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project	completed	N/A	10
	NCT04464642	Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis	unknown	PHASE4	110
	NCT03868072	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers	completed	PHASE1	40
	NCT03755466	Examination of Efficacy and Safety of Baricitinib in RA Patients	unknown	PHASE2	90
	NCT03440892	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	unknown	N/A	2,500
	NCT02996500	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	completed	PHASE2	269
	NCT03011281	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	unknown	N/A	378
	NCT02321930	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	completed	PHASE4	37
	NCT02566967	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	completed	PHASE3	20
	NCT02281552	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	completed	PHASE3	209
	NCT02147587	A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate	completed	PHASE2	112
	NCT01932372	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	completed	N/A	9,968
	NCT01741493	A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	completed	PHASE1	67
	NCT01164579	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	completed	PHASE2	109
	NCT03414502	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	recruiting	PHASE3	400
	NCT01745055	Co-Administration Of Methotrexate And CP-690,550	completed	PHASE1	12
Ulcerative Colitis	NCT06625450	TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS	not yet recruiting	PHASE4	75
	NCT06095128	A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	recruiting	PHASE4	65
	NCT05112263	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis	unknown	NA	96
	NCT05431283	Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy	unknown	N/A	100
	NCT05728008	Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.	completed	N/A	100
	NCT05313620	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	recruiting	PHASE4	30
	NCT05186623	Prediction Model for Response to Biologics and Small Molecular Agent for UC	recruiting	N/A	300
	NCT04624230	Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis	active not recruiting	PHASE3	118
	NCT04424303	Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis	completed	N/A	152
	NCT04338204	Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden	completed	N/A	102
	NCT03885713	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	completed	PHASE4	180
	NCT01458951	A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis	completed	PHASE3	547
	NCT01465763	A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis	completed	PHASE3	614
Healthy	NCT04985955	A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3	completed	PHASE1	12
	NCT04552197	A Study of JNJ-64251330 in Healthy Participants	completed	PHASE1	36
	NCT04338711	A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations	completed	PHASE1	23
	NCT04111614	A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.	completed	PHASE1	12
	NCT04403776	PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation	completed	PHASE1	26
	NCT03112148	PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations	completed	PHASE1	24
	NCT02487433	A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers	completed	PHASE1	18
	NCT02084875	A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers	completed	PHASE1	24
	NCT01731327	A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers	completed	PHASE1	20
	NCT01599377	Tofacitinib Bioequivalence Study Comparing Tablets And Capsules	completed	PHASE1	50
	NCT01499004	A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers	completed	PHASE1	30
Psoriatic Arthritis	NCT07406035	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis	not yet recruiting	PHASE2	156
	NCT06176508	Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis	recruiting	PHASE2	160
	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
	NCT04610476	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	unknown	PHASE3	270
	NCT04062695	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement	unknown	PHASE2	80
	NCT03486457	Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis	completed	PHASE3	204
	NCT03736161	Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis	completed	PHASE3	61
	NCT01877668	Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study	completed	PHASE3	422
	NCT01882439	Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors	completed	PHASE3	395
Alopecia Areata	NCT07406204	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	not yet recruiting	PHASE4	78
	NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150
	NCT06278402	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	completed	PHASE3	30
	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
	NCT03800979	Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata	completed	PHASE4	19
	NCT02812342	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	PHASE2	10
	NCT02299297	Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis	completed	PHASE2	12
	NCT02312882	Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	NA	40
Arthritis, Rheumatoid	NCT04928066	The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA	completed	PHASE4	100
	NCT03970837	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	terminated	PHASE3	1,764
	NCT03980483	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	completed	PHASE3	1,537
	NCT03981900	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	completed	N/A	314
	NCT03387423	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	completed	N/A	1,459
	NCT02092467	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	completed	PHASE4	4,372
Psoriasis	NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10
	NCT07261306	Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis	recruiting	EARLY_PHASE1	75
	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
	NCT01831466	Tofacitinib Ointment For Chronic Plaque Psoriasis	completed	PHASE2	476
	NCT01736696	Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis	completed	PHASE1	59
Takayasu Arteritis	NCT06498089	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	recruiting	PHASE4	124
	NCT05749666	Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis	unknown	PHASE3	50
	NCT05151848	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	unknown	PHASE4	100
	NCT05102448	Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis	recruiting	PHASE4	76
	NCT04299971	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	unknown	PHASE4	130
COVID-19	NCT04412252	Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy	withdrawn	PHASE2	0
	NCT04390061	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia	unknown	PHASE2	116
	NCT05638932	Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments	completed	N/A	1,442
	NCT04750317	Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia	completed	PHASE2	414
Alopecia Universalis	NCT07406204	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	not yet recruiting	PHASE4	78
	NCT06278402	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	completed	PHASE3	30
	NCT02812342	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	PHASE2	10
	NCT02312882	Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	NA	40
Systemic Lupus Erythematosus	NCT03288324	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	completed	PHASE1/PHASE2	13
	NCT03159936	Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)	terminated	EARLY_PHASE1	5
	NCT02535689	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus	completed	PHASE1	34
Axial Spondyloarthritis	NCT06112665	ToFAcitinib in Early Active Axial SpondyloarThritis:	recruiting	PHASE4	104
	NCT06310057	Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study	completed	PHASE4	92
	NCT03738956	Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial	unknown	PHASE2/PHASE3	30
Atopic Dermatitis	NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10
	NCT06465732	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	not yet recruiting	PHASE4	220
	NCT05487963	Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis	completed	PHASE1/PHASE2	40
Alopecia Totalis	NCT06278402	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	completed	PHASE3	30
	NCT02812342	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	PHASE2	10
	NCT02312882	Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	NA	40
Hidradenitis Suppurativa	NCT06707246	A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients	recruiting	NA	60
	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
Active Ankylosing Spondylitis	NCT05814939	Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.	completed	PHASE2	180
	NCT04876781	Korean Post-marketing Surveillance for Xeljanz XR	recruiting	N/A	200
Ankylosing Spondylitis	NCT03502616	Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)	completed	PHASE3	270
	NCT01786668	Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis	completed	PHASE2	208
Polymyalgia Rheumatica	NCT06172361	Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica	recruiting	PHASE3	98
	NCT04799262	Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica	completed	PHASE2	14
Cutaneous Lupus	NCT05048238	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	completed	PHASE1	7
	NCT03288324	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	completed	PHASE1/PHASE2	13
Juvenile Idiopathic Arthritis	NCT02592434	Efficacy Study Of Tofacitinib In Pediatric JIA Population	completed	PHASE3	225
	NCT01500551	Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis	completed	PHASE2/PHASE3	302
Sjogren's Syndrome	NCT07281456	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease	recruiting	PHASE2	60
	NCT04496960	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome	active not recruiting	PHASE1/PHASE2	23
Alopecia Totalis (AT)	NCT07406204	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	not yet recruiting	PHASE4	78
	NCT02197455	Tofacitnib for the Treatment of Alopecia Areata and Variants	completed	PHASE2	30
Psoriasis Vulgaris	NCT02193815	A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	completed	PHASE1	15
	NCT01831466	Tofacitinib Ointment For Chronic Plaque Psoriasis	completed	PHASE2	476
Dermatomyositis	NCT06438679	3T Therapy in the Treatment of MDA5-positive Dermatomyositis	enrolling by invitation	PHASE4	133
	NCT03002649	Study of Tofacitinib in Refractory Dermatomyositis	completed	PHASE1	10
Granulomatosis With Polyangiitis	NCT04871191	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	recruiting	PHASE3	42
	NCT04944524	Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA	unknown	PHASE4	66
Toxic Epidermal Necrolysis	NCT06119490	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis	recruiting	EARLY_PHASE1	30
	NCT06474078	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	completed	NA	20
Down Syndrome	NCT05662228	Therapies for Down Syndrome Regression Disorder	active not recruiting	PHASE2	66
	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
Vitiligo	NCT07044141	Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo	active not recruiting	PHASE1	20
	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
Atopic Dermatitis (AD)	NCT06923228	A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis	completed	PHASE2	3
	NCT06810050	Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis	completed	PHASE2	180
Depression	NCT04141904	Tofacitinib in Depression (TIDE)	terminated	PHASE1/PHASE2	2
Dermatitis, Atopic	NCT02001181	Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)	completed	PHASE2	69
Diaphragm Injury	NCT03681275	Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction	recruiting	PHASE2	70
Diffuse Large B Cell Lymphoma	NCT05348213	Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	76
Discoid Lupus Erythematosus	NCT03159936	Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)	terminated	EARLY_PHASE1	5
Drug Use	NCT04973033	Effect of Tofacitinib in Treating ANCA-associated Vasculitis	completed	NA	10
Effect of Drug	NCT04799262	Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica	completed	PHASE2	14
Efficacy of Tofacitinib in the Systemic Sclerosis	NCT06044844	Effectiveness of Tofacitinib in Systemic Sclerosis	unknown	PHASE2	44
Epithelioid Mesothelioma	NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	completed	PHASE1	19
Erythematotelangiectatic Rosacea	NCT07343635	The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea	recruiting	NA	186
Extensive Alopecia Areata	NCT06157905	Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata	completed	EARLY_PHASE1	9
Extranodal NK/T-cell Lymphoma	NCT03598959	Tofacitinib Combined With Chidamide in R/R ENKTCL	unknown	PHASE2	20
Frontal Fibrosing Alopecia	NCT06202560	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study	completed	NA	11
Glioblastoma	NCT05326464	Tofacitinib in Recurrent GBM Patients	active not recruiting	PHASE3	17
Glucocorticoid Resistant ICIs-related Myocarditis	NCT06393972	The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis	not yet recruiting	PHASE2	25
Granuloma Annulare	NCT03910543	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare	completed	PHASE1	15
Graves Ophthalmopathy	NCT07547930	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	recruiting	PHASE2	8
Graves Orbitopathy	NCT07547930	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	recruiting	PHASE2	8
Healthy Subjects	NCT04468425	Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study	completed	PHASE1	14
Idiopathic Inflammatory Myopathies	NCT05400889	Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies	unknown	PHASE2	10
IgG4-related Disease	NCT05625581	Tofatib Treatment for IgG4-related Disease	unknown	N/A	40
ILD	NCT04311567	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	terminated	PHASE4	3
Ileal Pouch	NCT04580277	Tofacitinib For Treatment Of Chronic Pouchitis	terminated	PHASE2	6
Ileal Pouchitis	NCT04580277	Tofacitinib For Treatment Of Chronic Pouchitis	terminated	PHASE2	6
Immune-Mediated Colitis	NCT04768504	Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study	terminated	PHASE2	2
Immunomodulation	NCT01736696	Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis	completed	PHASE1	59
Inflamatory Bowel Disease	NCT07487311	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	recruiting	N/A	80
Inflammation	NCT04141904	Tofacitinib in Depression (TIDE)	terminated	PHASE1/PHASE2	2
Inflammatory Bowel Diseases	NCT03885713	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	completed	PHASE4	180
Inflammatory Gastrointestinal Disease	NCT05104723	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	completed	PHASE1/PHASE2	10
Inflammatory Lung Disease	NCT05104723	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	completed	PHASE1/PHASE2	10
Inflammatory Skin Disease	NCT05104723	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	completed	PHASE1/PHASE2	10
Inhibition	NCT04299971	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	unknown	PHASE4	130
Interstitial Lung Disease	NCT05246293	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	unknown	PHASE2	60
Interstitial Lung Disease Due to Systemic Disease (Disorder)	NCT04311567	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	terminated	PHASE4	3
Itch	NCT06201715	Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	unknown	NA	24
JAK-STAT Pathway Deregulation	NCT04973033	Effect of Tofacitinib in Treating ANCA-associated Vasculitis	completed	NA	10
Janus Kinase Inhibitors	NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150
Juvenile Idiopathic Arthritis (JIA)	NCT07211932	Tofacitinib in Juvenile Idiopathic Arthritis	not yet recruiting	N/A	58
Kidney Transplantation	NCT01375127	Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients	completed	N/A	83
LAL	NCT07522801	A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL	not yet recruiting	PHASE2	93
Lichen Planopilaris of Scalp	NCT06202560	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study	completed	NA	11
Major Adverse Cardiac Events	NCT07554820	Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	recruiting	PHASE4	120
Methotrexate	NCT04299971	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	unknown	PHASE4	130
Moderate to Severe Rheumatoid Arthritis	NCT07008846	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	96
Myasthenia Gravis, Generalized	NCT04431895	Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study	completed	EARLY_PHASE1	19
Nail Psoriasis	NCT07313072	Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study	not yet recruiting	PHASE2	10
Neoplasms With Mesothelin Expression	NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	completed	PHASE1	19
Oral Lichen Planus	NCT07131813	Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus	recruiting	PHASE4	60
Palmoplantar Pustulosis (PPP)	NCT07530367	A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis	not yet recruiting	PHASE3	135
Plaque Psoriasis	NCT01710046	Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis	completed	PHASE2	12
Pneumonitis, Interstitial	NCT04390061	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia	unknown	PHASE2	116
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	NCT06654882	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	recruiting	PHASE3	400
Pouchitis	NCT04580277	Tofacitinib For Treatment Of Chronic Pouchitis	terminated	PHASE2	6
Primary Cutaneous Amyloidosis	NCT06998875	A Prospective Cohort Study on Primary Cutaneous Amyloidosis	recruiting	PHASE4	56
Primary Sjögren's Syndrome	NCT05087589	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome	unknown	PHASE2	10
Prurigo Nodularis	NCT06201715	Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	unknown	NA	24
RA	NCT04311567	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	terminated	PHASE4	3
Reduction	NCT04610476	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	unknown	PHASE3	270
Regression	NCT05662228	Therapies for Down Syndrome Regression Disorder	active not recruiting	PHASE2	66
Rhematoid Arthritis	NCT02187055	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	completed	PHASE4	1,152
Rheumatic Arthritis	NCT04485325	Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients	completed	PHASE4	92
Rheumatic Disease	NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	not yet recruiting	PHASE2	80
Rheumatoid Arthritis (RA	NCT06945666	A Study of Iguratimod in Combination With Tofacitinib in RA Patients	not yet recruiting	PHASE4	200
Rhumatoid Arthisis	NCT06687551	JAK Inhibitor Dose TAPering Strategy Study	not yet recruiting	PHASE4	308
Sacroilitis	NCT04062695	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement	unknown	PHASE2	80
Safety Issues	NCT04799262	Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica	completed	PHASE2	14
Sarcoidosis	NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	completed	PHASE1	5
Sarcoidosis Lung	NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	completed	PHASE1	5
Sarcoidosis, Pulmonary	NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	completed	PHASE1	5
SARS-COv2 Related Interstitial Pneumonia	NCT04332042	TOFAcitinib in SARS-CoV2 Pneumonia	unknown	PHASE2	50
Scleritis	NCT03580343	Tofacitinib for Inflammatory Eye Disease	unknown	PHASE2	5
Scleroderma	NCT03274076	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	completed	PHASE1/PHASE2	15
Scleroderma, Systemic	NCT07472166	Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate	completed	PHASE4	34
Spondylarthritis	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
Spondylitis	NCT04062695	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement	unknown	PHASE2	80
Spondyloarthritis	NCT03504072	Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh	unknown	PHASE4	174
Spondyloarthritis, Axial	NCT06114407	Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib	unknown	PHASE2	184
Spondyloarthropathy	NCT05431283	Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy	unknown	N/A	100
Stevens-Johnson Syndrome	NCT06474078	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	completed	NA	20
Systemic Sclerosis	NCT03274076	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	completed	PHASE1/PHASE2	15
Telitacicept	NCT06979271	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	recruiting	N/A	20
Thromboembolism	NCT05313620	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	recruiting	PHASE4	30
Thyroid Eye Disease, TED	NCT07547930	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	recruiting	PHASE2	8
Treatment	NCT04299971	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	unknown	PHASE4	130
Treatment Compliance	NCT06979271	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	recruiting	N/A	20
Ulcerative Colitis Acute	NCT04925973	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	active not recruiting	PHASE2	24
Uveitis	NCT03580343	Tofacitinib for Inflammatory Eye Disease	unknown	PHASE2	5
Vitiligo, Generalized	NCT07055529	Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.	not yet recruiting	EARLY_PHASE1	64
Withdrawal	NCT04610476	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	unknown	PHASE3	270
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects	NCT03103412	TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)	completed	PHASE1	32
Active Moderate to Severe Rheumatoid Arthritis	NCT04876781	Korean Post-marketing Surveillance for Xeljanz XR	recruiting	N/A	200
Active Psoriatic Arthritis	NCT04876781	Korean Post-marketing Surveillance for Xeljanz XR	recruiting	N/A	200
Acute Severe Ulcerative Colitis	NCT07297069	Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial	not yet recruiting	PHASE2	60
Adenocarcinoma, Pancreatic	NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	completed	PHASE1	19
Alopecia Areata (AA)	NCT02197455	Tofacitnib for the Treatment of Alopecia Areata and Variants	completed	PHASE2	30
Alopecia Areata(AA)	NCT07101471	Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation	completed	N/A	296
Alopecia Totalis/Universalis	NCT07101471	Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation	completed	N/A	296
Alopecia Universalis (AU)	NCT02197455	Tofacitnib for the Treatment of Alopecia Areata and Variants	completed	PHASE2	30
Amyotrophic Lateral Sclerosis	NCT06689982	Tofacitinib in Patients With Amyotrophic Lateral Sclerosis	not yet recruiting	EARLY_PHASE1	12
ANCA Associated Vasculitis	NCT04973033	Effect of Tofacitinib in Treating ANCA-associated Vasculitis	completed	NA	10
Aneurysm	NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	recruiting	PHASE2	81
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis	NCT04871191	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	recruiting	PHASE3	42
Arthritis Juvenile Idiopathic	NCT03000439	A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA	completed	PHASE3	100
Arthritis Rheumatoid	NCT04721821	Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.	completed	N/A	7,807
Arthritis, Psoriatic	NCT01976364	Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis	completed	PHASE3	686
Atopic Dermatitis / Eczema	NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47
Behcet Syndrome, Vascular Type	NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	recruiting	PHASE2	81
Blau Syndrome	NCT06688838	Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome	enrolling by invitation	N/A	24
Cholangiocarcinoma, Extrahepatic	NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	completed	PHASE1	19
Chronic Granulomatous Disease	NCT05104723	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	completed	PHASE1/PHASE2	10
Clinically Amyopathic Dermatomyisitis(CAMD)	NCT04613219	Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease	unknown	N/A	80
COVID-19 Pneumonia	NCT04415151	Tofacitinib for Treatment of Moderate COVID-19	terminated	PHASE2	24
Covid19	NCT04469114	Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia	completed	PHASE3	289
Crohn Disease	NCT03885713	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	completed	PHASE4	180
Cutaneous Leishmaniasis, American	NCT06011343	Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis	unknown	PHASE2/PHASE3	22
Cutaneous Sarcoidosis	NCT03910543	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare	completed	PHASE1	15
Cutaneous T-Cell Lymphoma	NCT06698822	A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA	recruiting	PHASE2	20

All Tofacitinib Clinical Trials (189)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07522801	A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL	not yet recruiting	PHASE2	93	Philippe ROUSSELOT
NCT07055529	Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.	not yet recruiting	EARLY_PHASE1	64	Hayat Abad Medical Complex, Peshawar
NCT07406035	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis	not yet recruiting	PHASE2	156	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT07547930	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	recruiting	PHASE2	8	The First Affiliated Hospital of Xiamen University
NCT07530367	A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis	not yet recruiting	PHASE3	135	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07313072	Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study	not yet recruiting	PHASE2	10	Hexsel Dermatology Clinic
NCT07406204	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	not yet recruiting	PHASE4	78	Hayat Abad Medical Complex, Peshawar
NCT07343635	The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea	recruiting	NA	186	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NCT06654882	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	recruiting	PHASE3	400	Duke University
NCT07487311	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	recruiting	N/A	80	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10	University of California, San Francisco
NCT07297069	Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial	not yet recruiting	PHASE2	60	Asian Institute of Gastroenterology, India
NCT07211932	Tofacitinib in Juvenile Idiopathic Arthritis	not yet recruiting	N/A	58	Consorci Sanitari de l'Alt Penedès i Garraf
NCT07281456	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease	recruiting	PHASE2	60	National Institute of Dental and Craniofacial Research (NIDCR)
NCT07554820	Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	recruiting	PHASE4	120	Shaikh Zayed Hospital, Lahore
NCT07131813	Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus	recruiting	PHASE4	60	All India Institute of Medical Sciences, Bhubaneswar
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	not yet recruiting	PHASE2	80	NYU Langone Health
NCT07261306	Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis	recruiting	EARLY_PHASE1	75	Lahore General Hospital
NCT06945666	A Study of Iguratimod in Combination With Tofacitinib in RA Patients	not yet recruiting	PHASE4	200	Jie Chang
NCT04871191	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	recruiting	PHASE3	42	Assistance Publique - Hôpitaux de Paris
NCT06979271	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	recruiting	N/A	20	Zhejiang Provincial People's Hospital
NCT07008846	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	96	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06923228	A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis	completed	PHASE2	3	CAGE Bio Inc.
NCT06698822	A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA	recruiting	PHASE2	20	M.D. Anderson Cancer Center
NCT06998875	A Prospective Cohort Study on Primary Cutaneous Amyloidosis	recruiting	PHASE4	56	Army Medical University, China
NCT07044141	Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo	active not recruiting	PHASE1	20	Lahore General Hospital
NCT06465732	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	not yet recruiting	PHASE4	220	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06687551	JAK Inhibitor Dose TAPering Strategy Study	not yet recruiting	PHASE4	308	University Hospital, Toulouse
NCT07472166	Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate	completed	PHASE4	34	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06810050	Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis	completed	PHASE2	180	CAGE Bio Inc.
NCT06707246	A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients	recruiting	NA	60	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06689982	Tofacitinib in Patients With Amyotrophic Lateral Sclerosis	not yet recruiting	EARLY_PHASE1	12	Beijing Tiantan Hospital
NCT06625450	TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS	not yet recruiting	PHASE4	75	Post Graduate Institute of Medical Education and Research, Chandigarh
NCT06301373	Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis	recruiting	NA	130	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06393972	The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis	not yet recruiting	PHASE2	25	Shanghai Zhongshan Hospital
NCT06498089	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	recruiting	PHASE4	124	Shanghai Zhongshan Hospital
NCT06095128	A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	recruiting	PHASE4	65	Takeda
NCT06418529	A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis	completed	N/A	21,340	Pfizer
NCT06201715	Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	unknown	NA	24	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06438679	3T Therapy in the Treatment of MDA5-positive Dermatomyositis	enrolling by invitation	PHASE4	133	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06176508	Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis	recruiting	PHASE2	160	Hansoh BioMedical R&D Company
NCT06172361	Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica	recruiting	PHASE3	98	Zhejiang University
NCT06044844	Effectiveness of Tofacitinib in Systemic Sclerosis	unknown	PHASE2	44	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06202560	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study	completed	NA	11	Institute of Dermatology, Thailand
NCT06020144	A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs	active not recruiting	PHASE3	459	Hangzhou Highlightll Pharmaceutical Co., Ltd
NCT06112665	ToFAcitinib in Early Active Axial SpondyloarThritis:	recruiting	PHASE4	104	Charite University, Berlin, Germany
NCT06114407	Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib	unknown	PHASE2	184	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06011343	Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis	unknown	PHASE2/PHASE3	22	Hospital Universitário Professor Edgard Santos
NCT06119490	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis	recruiting	EARLY_PHASE1	30	Peng Zhang
NCT06278402	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	completed	PHASE3	30	Jinnah Hospital
NCT05112263	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis	unknown	NA	96	Post Graduate Institute of Medical Education and Research, Chandigarh
NCT05662228	Therapies for Down Syndrome Regression Disorder	active not recruiting	PHASE2	66	University of Colorado, Denver
NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	recruiting	PHASE2	81	Peking Union Medical College Hospital
NCT05814939	Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.	completed	PHASE2	180	Jiangsu vcare pharmaceutical technology co., LTD
NCT05803135	Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis	unknown	PHASE4	138	Nanfang Hospital, Southern Medical University
NCT05749666	Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis	unknown	PHASE3	50	Chinese SLE Treatment And Research Group
NCT05625581	Tofatib Treatment for IgG4-related Disease	unknown	N/A	40	Changhai Hospital
NCT05487963	Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis	completed	PHASE1/PHASE2	40	CAGE Bio Inc.
NCT05326464	Tofacitinib in Recurrent GBM Patients	active not recruiting	PHASE3	17	University of Texas Southwestern Medical Center
NCT05048238	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	completed	PHASE1	7	National Institute of Allergy and Infectious Diseases (NIAID)
NCT05104723	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	completed	PHASE1/PHASE2	10	National Institute of Allergy and Infectious Diseases (NIAID)
NCT05246293	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	unknown	PHASE2	60	National Institute of Respiratory Diseases, Mexico
NCT06157905	Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata	completed	EARLY_PHASE1	9	Services Institute of Medical Sciences, Pakistan
NCT06474078	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	completed	NA	20	Chang Gung Memorial Hospital
NCT05165771	Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment	withdrawn	PHASE2	0	Gilead Sciences
NCT05400889	Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies	unknown	PHASE2	10	Peking University People's Hospital
NCT05606107	To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks	unknown	PHASE4	230	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05348213	Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma	recruiting	PHASE2	76	Ruijin Hospital
NCT05431283	Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy	unknown	N/A	100	Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
NCT05728008	Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.	completed	N/A	100	IRCCS San Raffaele
NCT05313620	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	recruiting	PHASE4	30	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
NCT04768504	Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study	terminated	PHASE2	2	Khashayar Esfahani
NCT05133297	The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis	completed	PHASE2	101	Hangzhou Highlightll Pharmaceutical Co., Ltd
NCT05186623	Prediction Model for Response to Biologics and Small Molecular Agent for UC	recruiting	N/A	300	Asan Medical Center
NCT04876781	Korean Post-marketing Surveillance for Xeljanz XR	recruiting	N/A	200	Pfizer
NCT05151848	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	unknown	PHASE4	100	Chinese SLE Treatment And Research Group
NCT06310057	Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study	completed	PHASE4	92	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT05087589	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome	unknown	PHASE2	10	Peking University People's Hospital
NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841	Jeffrey Curtis
NCT05102448	Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis	recruiting	PHASE4	76	Shanghai Zhongshan Hospital
NCT04624230	Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis	active not recruiting	PHASE3	118	Pfizer
NCT04985955	A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3	completed	PHASE1	12	Janssen Research & Development, LLC
NCT04944524	Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA	unknown	PHASE4	66	Shanghai Zhongshan Hospital
NCT04925973	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	active not recruiting	PHASE2	24	McMaster University
NCT04927000	The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis	unknown	PHASE4	170	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04496960	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome	active not recruiting	PHASE1/PHASE2	23	National Institute of Dental and Craniofacial Research (NIDCR)
NCT04798287	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	completed	N/A	105,711	Brigham and Women's Hospital
NCT04772248	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints	completed	N/A	105,711	Brigham and Women's Hospital
NCT04580277	Tofacitinib For Treatment Of Chronic Pouchitis	terminated	PHASE2	6	Cedars-Sinai Medical Center
NCT04721821	Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.	completed	N/A	7,807	Pfizer
NCT04799262	Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica	completed	PHASE2	14	RenJi Hospital
NCT04424303	Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis	completed	N/A	152	Pfizer
NCT04311567	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	terminated	PHASE4	3	Vastra Gotaland Region
NCT04246372	Tofacitinib for Immune Skin Conditions in Down Syndrome	completed	PHASE2	47	University of Colorado, Denver
NCT04610476	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	unknown	PHASE3	270	University of Erlangen-Nürnberg Medical School
NCT04468425	Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study	completed	PHASE1	14	TWi Biotechnology, Inc.
NCT04415151	Tofacitinib for Treatment of Moderate COVID-19	terminated	PHASE2	24	Yale University
NCT04613219	Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease	unknown	N/A	80	Jing Liang
NCT04469114	Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia	completed	PHASE3	289	Hospital Israelita Albert Einstein
NCT04338204	Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden	completed	N/A	102	Pfizer
NCT04552197	A Study of JNJ-64251330 in Healthy Participants	completed	PHASE1	36	Janssen Research & Development, LLC
NCT04529876	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept	completed	N/A	29,464	Brigham and Women's Hospital
NCT07101471	Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation	completed	N/A	296	NanoAlvand
NCT04062695	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement	unknown	PHASE2	80	Charite University, Berlin, Germany
NCT04413617	TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	completed	PHASE2	460	Pfizer
NCT04412252	Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy	withdrawn	PHASE2	0	Pfizer
NCT04390061	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia	unknown	PHASE2	116	Università Politecnica delle Marche
NCT04338711	A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations	completed	PHASE1	23	Pfizer
NCT05638932	Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments	completed	N/A	1,442	Aetion, Inc.
NCT04431895	Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study	completed	EARLY_PHASE1	19	Huashan Hospital
NCT04750317	Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia	completed	PHASE2	414	I.M. Sechenov First Moscow State Medical University
NCT04449224	Comparative Effectiveness of Targeted Therapy in RA Patients	unknown	N/A	506	Hanyang University
NCT04332042	TOFAcitinib in SARS-CoV2 Pneumonia	unknown	PHASE2	50	Università Politecnica delle Marche
NCT04928066	The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA	completed	PHASE4	100	Qilu Hospital of Shandong University
NCT03976245	Advanced Therapeutics in Rheumatoid Arthritis (RA)	recruiting	PHASE4	144	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT04299971	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	unknown	PHASE4	130	Shanghai Zhongshan Hospital
NCT04175886	Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project	completed	N/A	10	University Hospital, Lille
NCT04141904	Tofacitinib in Depression (TIDE)	terminated	PHASE1/PHASE2	2	University of Oxford
NCT04973033	Effect of Tofacitinib in Treating ANCA-associated Vasculitis	completed	NA	10	Shanghai Zhongshan Hospital
NCT04485325	Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients	completed	PHASE4	92	Dr. Frank Behrens
NCT04111614	A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.	completed	PHASE1	12	Pfizer
NCT03885713	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	completed	PHASE4	180	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
NCT03681275	Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction	recruiting	PHASE2	70	Stanford University
NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	completed	PHASE1	19	National Cancer Institute (NCI)
NCT04464642	Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis	unknown	PHASE4	110	Dr. Mohammad Mamun Khan
NCT03970837	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	terminated	PHASE3	1,764	GlaxoSmithKline
NCT03980483	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	completed	PHASE3	1,537	GlaxoSmithKline
NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	completed	PHASE1	5	Oregon Health and Science University
NCT03910543	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare	completed	PHASE1	15	Yale University
NCT03580343	Tofacitinib for Inflammatory Eye Disease	unknown	PHASE2	5	Washington University School of Medicine
NCT03868072	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers	completed	PHASE1	40	Chong Kun Dang Pharmaceutical
NCT03800979	Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata	completed	PHASE4	19	Institute of Dermatology, Thailand
NCT03981900	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	completed	N/A	314	Pfizer
NCT03598959	Tofacitinib Combined With Chidamide in R/R ENKTCL	unknown	PHASE2	20	Sichuan University
NCT04403776	PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation	completed	PHASE1	26	Pfizer
NCT03755466	Examination of Efficacy and Safety of Baricitinib in RA Patients	unknown	PHASE2	90	Shinshu University
NCT03486457	Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis	completed	PHASE3	204	Pfizer
NCT03502616	Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)	completed	PHASE3	270	Pfizer
NCT03000439	A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA	completed	PHASE3	100	Pfizer
NCT03504072	Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh	unknown	PHASE4	174	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT03387423	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	completed	N/A	1,459	Pfizer
NCT03440892	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	unknown	N/A	2,500	Vastra Gotaland Region
NCT03274076	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	completed	PHASE1/PHASE2	15	University of Michigan
NCT03736161	Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis	completed	PHASE3	61	Globe Pharmaceuticals Limited
NCT03112148	PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations	completed	PHASE1	24	Pfizer
NCT03738956	Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial	unknown	PHASE2/PHASE3	30	Globe Pharmaceuticals Limited
NCT03288324	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	completed	PHASE1/PHASE2	13	Children's Hospital Medical Center, Cincinnati
NCT03103412	TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)	completed	PHASE1	32	Theravance Biopharma
NCT03159936	Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)	terminated	EARLY_PHASE1	5	Tufts Medical Center
NCT03002649	Study of Tofacitinib in Refractory Dermatomyositis	completed	PHASE1	10	Johns Hopkins University
NCT06688838	Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome	enrolling by invitation	N/A	24	Tongji Hospital
NCT02996500	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	completed	PHASE2	269	Pfizer
NCT03011281	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	unknown	N/A	378	Hanyang University
NCT02812342	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	PHASE2	10	Yale University
NCT02592434	Efficacy Study Of Tofacitinib In Pediatric JIA Population	completed	PHASE3	225	Pfizer
NCT02321930	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	completed	PHASE4	37	University of California, Los Angeles
NCT02535689	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus	completed	PHASE1	34	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT02487433	A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers	completed	PHASE1	18	Pfizer
NCT02566967	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	completed	PHASE3	20	Norman B. Gaylis, MD
NCT02299297	Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis	completed	PHASE2	12	Columbia University
NCT02312882	Tofacitinib for the Treatment of Alopecia Areata and Its Variants	completed	NA	40	Stanford University
NCT02281552	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	completed	PHASE3	209	Pfizer
NCT02193815	A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	completed	PHASE1	15	Pfizer
NCT02187055	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	completed	PHASE4	1,152	Pfizer
NCT02197455	Tofacitnib for the Treatment of Alopecia Areata and Variants	completed	PHASE2	30	Yale University
NCT02147587	A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate	completed	PHASE2	112	Pfizer
NCT02084875	A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers	completed	PHASE1	24	Pfizer
NCT02092467	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	completed	PHASE4	4,372	Pfizer
NCT01976364	Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis	completed	PHASE3	686	Pfizer
NCT01877668	Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study	completed	PHASE3	422	Pfizer
NCT02001181	Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)	completed	PHASE2	69	Pfizer
NCT01882439	Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors	completed	PHASE3	395	Pfizer
NCT01932372	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	completed	N/A	9,968	Pfizer
NCT01831466	Tofacitinib Ointment For Chronic Plaque Psoriasis	completed	PHASE2	476	Pfizer
NCT01786668	Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis	completed	PHASE2	208	Pfizer
NCT01710046	Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis	completed	PHASE2	12	Pfizer
NCT01500551	Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis	completed	PHASE2/PHASE3	302	Pfizer
NCT01741493	A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	completed	PHASE1	67	AbbVie (prior sponsor, Abbott)
NCT01731327	A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers	completed	PHASE1	20	Pfizer
NCT01458951	A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis	completed	PHASE3	547	Pfizer
NCT01599377	Tofacitinib Bioequivalence Study Comparing Tablets And Capsules	completed	PHASE1	50	Pfizer
NCT01465763	A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis	completed	PHASE3	614	Pfizer
NCT01499004	A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers	completed	PHASE1	30	Pfizer
NCT01375127	Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients	completed	N/A	83	Pfizer
NCT01164579	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	completed	PHASE2	109	Pfizer
NCT03414502	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	recruiting	PHASE3	400	University of Nebraska
NCT01745055	Co-Administration Of Methotrexate And CP-690,550	completed	PHASE1	12	Pfizer
NCT01736696	Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis	completed	PHASE1	59	Pfizer

Where to Participate: All Tofacitinib Trial Sites in the U.S. (47 sites across 24 states)

Every actively recruiting Tofacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialsits	Dothan36301	NCT06095128	Map
AZ	GI Alliance Sun City	Sun City85351	NCT06095128	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06095128	Map
CA	Hoag Hospital Newport Beach	Newport Beach92663	NCT06095128	Map
CA	University of California San Francisco Pediatric Rheumatology	San Francisco94158	NCT06654882	Map
CA	Stanford University Medical Center	Stanford94305	NCT03681275	Map
FL	University of Florida	Gainesville32610	NCT06654882	Map
FL	Endoscopic Research Inc	Orlando32803	NCT06095128	Map
FL	Alliance Clinical Research of Tampa, LLC	Tampa33615	NCT06095128	Map
GA	Gastroenterology Consultants, P.C.	Roswell30076	NCT06095128	Map
IL	University of Chicago Medicine	Chicago60637	NCT06095128	Map
IL	GI Alliance - Illinois Gastroenterology Group - Glenview	Glenview60026	NCT06095128	Map
IL	GI Alliance - Illinois Gastroenterology Group LLC - Gurnee	Gurnee60031	NCT06095128	Map
KS	University of Kansas Medical Center	Kansas City66160	NCT06095128	Map
KY	University of Louisville	Louisville40202	NCT06095128	Map
LA	GI Alliance	Metairie70006	NCT06095128	Map
LA	Tulane University	New Orleans70112	NCT06095128	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07281456	Map
MD	Capital Digestive Care - MGG Group - Chevy Chase Clinical Research	Chevy Chase20815	NCT06095128	Map
MI	Huron Gastroenterology Associates, P.C.	Ypsilanti48197	NCT06095128	Map
MN	MNGI Digestive Health, PA	Plymouth55446	NCT06095128	Map
MO	Mid-America Gastro-Intestinal Consultants	Kansas City64111	NCT06095128	Map
MO	BVL Clinical Research	Liberty64068	NCT06095128	Map
MO	Washington University School of Medicine	St Louis63110	NCT06095128	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03414502	Map
NJ	Hackensack Meridian Health - Joseph M. Sanzari Children's Hospital	Hackensack07601	NCT06654882	Map
NY	NYU Langone Health	New York10016	NCT06095128	Map
NY	Weill Cornell Medical College- New York Presbyterian Hospital	New York10065	NCT06095128	Map
NC	Digestive Health Partners	Asheville28801	NCT06095128	Map
NC	University of North Carolina	Chapel Hill27599	NCT06095128	Map
OH	University of Cincinnati	Cincinnati45627	NCT06095128	Map
OH	Nationwide Children's Hospital	Columbus43205	NCT06654882	Map
OH	Ohio Gastroenterology group, Inc.	Columbus43202	NCT06095128	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC.	Westlake44145	NCT06095128	Map
PA	Allegheny Health Network	Wexford15090	NCT06095128	Map
RI	University Gastroenterology	Providence02905	NCT06095128	Map
SD	Rapid City Medical Center, LLP	Rapid City57701	NCT06095128	Map
TX	GI Alliance - Digestive Health Associates of Texas	Dallas75044	NCT06095128	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06698822	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT06095128	Map
TX	GI Alliance - Mansfield	Mansfield76063	NCT06095128	Map
TX	Gastroenterology Research of San Antonio, LLC	San Antonio78229	NCT06095128	Map
TX	Texas Digestive Disease Consultants (TDDC), Southlake	Southlake76092	NCT06095128	Map
TX	Tyler Research Institute, LLC	Tyler75701	NCT06095128	Map
TX	GI Alliance - Webster	Webster77598	NCT06095128	Map
UT	University of Utah Health	Salt Lake City84108	NCT06095128	Map
WA	Washington Gastroenterology- GIA	Tacoma98405	NCT06095128	Map

Browse Tofacitinib Trials by State

Texas clinical trials Ohio clinical trials New York clinical trials California clinical trials Florida clinical trials Georgia clinical trials Illinois clinical trials Kansas clinical trials Kentucky clinical trials Louisiana clinical trials

tofacitinibrheumatoid arthritisulcerative colitishealthypsoriatic arthritisalopecia areataclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

Recent Tofacitinib updates

What Is Tofacitinib?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Tofacitinib Development Timeline

Conditions Under Study

All Tofacitinib Clinical Trials (189)

Sponsors

Where to Participate: All Tofacitinib Trial Sites in the U.S. (47 sites across 24 states)

Browse Tofacitinib Trials by State